(Q33341073)

25 July 2017

title

A 3-week schedule of gemcitabine plus cisplatin as induction chemotherapy for Stage III non-small cell lung cancer (English)

1 reference

25 July 2017

1 reference

M Rita Migliorino

1

1 reference

25 July 2017

Filippo De Marinis

2

1 reference

25 July 2017

Fabrizio Nelli

3

1 reference

25 July 2017

Franco Facciolo

4

1 reference

25 July 2017

M Vittoria Ammaturo

5

1 reference

25 July 2017

Antonio Cipri

6

1 reference

25 July 2017

Raffaele Belli

7

1 reference

25 July 2017

Ottavio Ariganello

8

1 reference

25 July 2017

Francesco Diana

9

1 reference

25 July 2017

Michele Di Molfetta

10

1 reference

25 July 2017

Olga Martelli

11

1 reference

25 July 2017

publication date

1 March 2002

1 reference

25 July 2017

1 reference

25 July 2017

volume

35

1 reference

25 July 2017

issue

3

1 reference

25 July 2017

page(s)

319-327

1 reference

Revisions in the International System for Staging Lung Cancer

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Multimodality treatment of stage IIIA non-small-cell lung carcinoma: a critical review of the literature and strategies for future research

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Weekly gemcitabine with monthly cisplatin: effective chemotherapy for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: A randomized phase III study of the Italian Lung Cancer Project

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Gemcitabine and cisplatin as induction regimen for patients with biopsy-proven stage IIIA N2 non-small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group (EORTC 08955).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

A three-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: a phase II randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Induction chemotherapy or chemoradiotherapy before surgery for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Preoperative chemotherapy for stage IIIa (N2) lung cancer: the Sloan-Kettering experience with 136 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage III unresectable non-small-cell lung cancer: results of the Toronto Phase II Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Long-term results of neoadjuvant ifosfamide, cisplatin, and etoposide combination in locally advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Induction treatment for resectable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine)

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900440-8

7 January 2021

10.1016/S0169-5002(01)00440-8

Identifiers

DOI

1 reference

25 July 2017

1 reference